PMVP NASDAQ
PMV Pharmaceuticals, Inc.
1W: +34.6%
1M: +42.1%
3M: +47.9%
YTD: +45.5%
1Y: +31.6%
3Y: -71.0%
5Y: -93.9%
$1.79
+0.04 (+2.29%)
Weekly Expected Move ±11.8%
$1
$2
$2
$2
$2
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
0.00
Neutral
0 bullish
0 neutral
0 bearish
Articles (24h)
0
No articles in the last 24 hours
0.90
Bullish
1 bullish
0 neutral
0 bearish
Articles (7d)
1
Daily Sentiment (7 Days)
Articles (15)
PMV Pharmaceuticals, Inc. (NASDAQ:PMVP) Stock Has Consensus Target Price of $4.33 According to Analysts
Should You Buy PMV Pharmaceuticals, Inc. (PMVP) After Golden Cross?
PMV Pharma prices $50M IPO at $1.21 per share
PMV Pharmaceuticals Announces Updated Promising Rezatapopt Monotherapy Interim Ovarian Cancer Data From PYNNACLE Phase 2 Pivotal Trial
PMV Pharmaceuticals (PMVP) Upgraded to Buy: What Does It Mean for the Stock?
PMV Pharmaceuticals Reports Second Quarter 2026 Financial Results and Corporate Highlights
PMV Pharmaceuticals (PMVP) Upgraded to Buy: Here's Why
PMV Pharmaceuticals (PMVP) Loses 26% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Why PMV Pharmaceuticals, Inc. (PMVP) Faces Funding Concerns Despite Positive Trial Activity
12 Health Care Stocks Moving In Wednesday's After-Market Session
PMV Pharmaceuticals Reports First Quarter 2026 Financial Results and Corporate Highlights
PMV Pharmaceuticals Announces Board Chair Transition
PMV Pharmaceuticals GAAP EPS of -$1.48 beats by $0.06
PMV Pharmaceuticals Reports Full Year 2025 Financial Results and Corporate Highlights
PMV Pharmaceuticals Reports Full Year 2025 Financial Results and Corporate Highlights